
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **July 29, 2015**

CARDAX, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction
of incorporation)

333-181719

(Commission
File Number)

45-4484428

(IRS Employer
Identification No.)

2800 Woodlawn Drive, Suite 129, Honolulu, Hawaii 96822

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(808) 457-1400**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

ITEM 8.01 Other Events.

On July 29, 2015, Cardax, Inc. (the “Company”) announced that its consumer health product candidates demonstrated superior oral bioavailability versus microalgal astaxanthin in a monkey study.

The single-dose pharmacokinetic study in non-human primates (monkeys) compared the bioavailability (plasma exposure) of the Company’s consumer health product candidates, CDX-085 and ASTX-1F, to microalgal astaxanthin, the predominate astaxanthin consumer health product form on the market. The study was conducted by top-tier contract research organizations.

CDX-085 is a patented pure ester of nature-identical astaxanthin and demonstrated more than two and one-half (2-1/2) times higher oral bioavailability than microalgal astaxanthin in the study. CDX-085 has approximately seven (7) times higher astaxanthin content per unit weight of the dietary ingredient than microalgal astaxanthin. The combination of CDX-085’s higher bioavailability and higher astaxanthin content translates into more than seventeen (17) times the relative strength per unit weight of the dietary ingredient compared to microalgal astaxanthin and should reduce the size/number of capsules or tablets required to achieve equivalent circulating levels of astaxanthin.

ASTX-1F is a proprietary formulation of nature-identical astaxanthin and demonstrated more than three (3) times higher oral bioavailability than microalgal astaxanthin in the study. ASTX-1F has approximately the same astaxanthin content per unit weight of the dietary ingredient as microalgal astaxanthin. The combination of ASTX-1F’s higher bioavailability and similar astaxanthin content translates into more than three (3) times the relative strength per unit weight of the dietary ingredient compared to microalgal astaxanthin and should reduce the size/number of capsules or tablets required to achieve equivalent circulating levels of astaxanthin.

Based on these results, the Company now intends to launch ASTX-1F as a first generation dietary supplement earlier in 2016 than previously expected, followed by CDX-085 as a second-generation dietary supplement and then OTC drug.

For more information, see the Company’s press release, dated July 29, 2015, which is filed as Exhibit 99.1 hereto and incorporated herein by reference.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS**Exhibit No. Description**

99.1 Press Released dated July 29, 2015

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 29, 2015

CARDAX, INC.

By: /s/ David G. Watumull

David G. Watumull
Chief Executive Officer

July 29, 2015



Cardax Product Candidates Demonstrate Superior Bioavailability vs. Microalgal Astaxanthin in Monkey Study

Results Support Accelerated Product Launch

HONOLULU— Cardax, Inc. (“Cardax”) (OTCQB:CDXI) announced today that its astaxanthin consumer health candidates CDX-085 and ASTX-1F demonstrated more than two and one-half times higher oral bioavailability than a leading microalgal astaxanthin product in a head-to-head monkey study. The study was conducted by top-tier contract research organizations and bioavailability was determined by measuring the plasma exposure of astaxanthin over four days following a single dose.

CDX-085 is a patented pure ester of nature-identical astaxanthin and ASTX-1F is a proprietary formulation of nature-identical astaxanthin. The enhanced bioavailability of CDX-085 and ASTX-1F compared to microalgal astaxanthin should reduce the size/number of capsules or tablets required to achieve equivalent circulating levels of astaxanthin.

Based on these results, the Company now intends to launch ASTX-1F as a first generation dietary supplement earlier in 2016 than previously expected, followed by CDX-085 as a second-generation dietary supplement and then OTC drug.

“We are pleased to see the superior oral bioavailability of our product candidates in a scientifically rigorous study,” said Cardax CEO, David G. Watumull. “CDX-085 and ASTX-1F provide an unmatched combination of bioavailability, purity, intellectual property, and large scale manufacturing advantages.”

About Cardax

Cardax is a development stage life sciences company that devotes substantially all of its efforts to developing consumer health and pharmaceutical products that it believes will provide many of the anti-inflammatory benefits of steroids or NSAIDS by targeting many of the same inflammatory pathways and mediators, but with exceptional safety profiles. Cardax is preparing proprietary nature-identical products and related derivatives by total synthesis to provide scalable, pure, and economical therapies for diseases where inflammation and oxidative stress are strongly implicated, including, but not limited to, osteoarthritis, rheumatoid arthritis, dyslipidemia, metabolic disease, diabetes, cardiovascular disease, hepatitis, cognitive decline, macular degeneration, and prostate disease. The initial primary focus of Cardax is its astaxanthin technologies. Astaxanthin is a powerful and safe naturally occurring anti-inflammatory and anti-oxidant without the adverse side effects typical of anti-inflammatory treatments using steroids or NSAIDS, including immune system suppression, liver damage, cardiovascular disease risk, and gastrointestinal bleeding. The safety and efficacy of Cardax’s product candidates have not been directly evaluated in clinical trials or confirmed by the FDA.

Safe Harbor

This release may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of our company, are generally identified by use of words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “seek,” “strive,” “try,” or future or conditional verbs such as “could,” “may,” “should,” “will,” “would,” or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Some of the factors that could cause our actual results to differ from our expectations or beliefs include, without limitation, the risks discussed from time to time in our filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, we undertake no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20150729005644/en/>

Cardax, Inc.

Janice Kam, 1-808-457-1400

press@cardaxpharma.com

Source: Cardax, Inc.
